Off-label use of rituximab in dermatology: pemphigus treatment

被引：12
|
作者：
Bomm, Lislaine [1 ]
Fracaroli, Taina Scalfoni [1 ]
Sodre, Joao Luz [1 ]
Bressan, Aline [1 ]
Gripp, Alexandre Carlos [1 ]
机构：
[1] State Univ Rio de Janeiro HUPE UERJ, Pedro Ernesto Univ Hosp, Rio De Janeiro, RJ, Brazil
来源：
ANAIS BRASILEIROS DE DERMATOLOGIA | 2013年 / 88卷 / 04期
关键词：
biological treatment; immunosuppressive agents; pemphigus;
D O I：
10.1590/abd1806-4841.20131905
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris and two cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m(2) once a week for 4 weeks, and that responded well to treatment.
引用
收藏
页码：676 / 678
页数：3
相关论文
共 50 条
  • [11] Off-Label Use of Rituximab in a Multipayer Insurance System
    Van Allen, Eliezer M.
    Miyake, Todd
    Gunn, Nathan
    Behler, Caroline M.
    Kohlwes, Jeff
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (02) : 76 - 79
  • [12] Extent and patterns of off-label use of rituximab for SLE
    Sanz, Inaki
    [J]. Nature Reviews Rheumatology, 2016, 12 (12) : 700 - U23
  • [13] The off-label use of infliximab in dermatology: a review of 22 cases
    Abikhair, M.
    Goh, M. S.
    Chong, A. H.
    Kelly, R.
    Saunders, H.
    Foley, P.
    Baker, C.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 2 - 2
  • [14] Dermatology - an Off-label Specialty with Risks
    Fritz, K.
    Salavastru, C.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 49 - 50
  • [15] Assessment off-label prescribing in dermatology
    Picard, D
    Carvalho, P
    Bonnavia, C
    Louin, L
    Josset, V
    Lauret, P
    Joly, P
    [J]. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2003, 130 (05): : 507 - 510
  • [16] Biologics in dermatology: Off-label indications
    Mitra, Debdeep
    Chopra, Ajay
    Saraswat, Neerja
    Mitra, Barnali
    Talukdar, Krishna
    Agarwal, Reetu
    [J]. INDIAN DERMATOLOGY ONLINE JOURNAL, 2020, 11 (03) : 319 - 327
  • [17] OFF-LABEL USE OF RITUXIMAB IN A TERTIARY REFERRAL RENAL UNIT
    Miles, R.
    Butterly, S.
    Pillans, P.
    Sturtevant, J.
    Johnson, D.
    Campbell, S.
    Hawley, C.
    Mudge, D.
    Van Eps, C.
    [J]. NEPHROLOGY, 2008, 13 : A106 - A106
  • [18] Off-label use of rituximab for systemic lupus erythematosus in Europe
    Ryden-Aulin, Monica
    Boumpas, Dimitrios
    Bultink, Irene
    Rubio, Jose Luis Callejas
    Caminal-Montero, Luis
    Castro, Antoni
    Colodro Ruiz, Agustin
    Doria, Andrea
    Domer, Thomas
    Gonzalez-Echavarri, Cristina
    Gremese, Elisa
    Houssiau, Frederic A.
    Huizinga, Tom
    Inana, Murat
    Isenberg, David
    Luliano, Annamaria
    Jacobsen, Soren
    Jimenez-Alonso, Juan
    Kovacs, Laszlo
    Mariette, Xavier
    Mosca, Marta
    Nived, Ola
    Oristrell, Joaquim
    Ramos-Casals, Manuel
    Rascon, Javier
    Ruiz-Irastorza, Guillermo
    Saez-Comet, Luis
    Salvador Cervello, Gonzalo
    Ruiz-Irastorza, Guillermo
    Saez-Comet, Luis
    Cervello, Gonzalo Salvador
    Sebastiani, Gian Domenico
    Squatrito, Danilo
    Szucs, Gabriella
    Voskuyl, Alexandre
    van Vollenhoven, Ronald
    [J]. LUPUS SCIENCE & MEDICINE, 2016, 3 (01):
  • [19] OFF-LABEL USE OF RITUXIMAB IN TWO SPANISH TERTIARY HOSPITALS
    Danes-Carreras, I.
    Agusti-Escasany, A.
    Santander, E.
    Guiu, J. M.
    Munne, M.
    Terrada, S.
    Ferrer, A. M.
    Figueras, A.
    Vallano-Ferraz, A.
    Bosch-Gil, J. A.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 65 - 66
  • [20] Off-label use of antipsychotics: Rethinking "off-label"
    Groleger, Urban
    [J]. PSYCHIATRIA DANUBINA, 2007, 19 (04) : 350 - 353
12345